Back to Search

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Participants With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

  • Protocol Number: 202212027
  • Principal Investigator: Pusic, Iskra
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions